Ocrevus is a medicine that represents a different scientific approach to treating multiple sclerosis. It targets a type of immune cell called the CD20-positive B cell that plays a key role in the disease.
OCREVUS has twice-yearly (six-monthly) dosing and is the first and only therapy approved for relapsing multiple sclerosis (RMS; including RRMS and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and primary progressive MS (PPMS). OCREVUS is approved in over 90 countries across North America, South America, the Middle East, Europe, as well as in Australia.
Ocrevus was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA), and approved by the FDA in March 2017 and by the European Commission in January 2018.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.